US Trade Judge Says Apple Can Sell Redesigned Blood Monitor

Why It Matters

The decision allows Apple to maintain a key health‑tracking feature while avoiding a costly import ban, and signals how tech firms can navigate patent barriers through product redesign. It also underscores the high stakes of medical‑device patents in the wearables market.

Key Takeaways

• ITC barred Apple’s original blood‑oxygen monitor in 2023.
• Redesigned monitor shifts processing to iPhone, avoiding infringement.
• Trade judge’s preliminary ruling permits continued sales of redesign.
• Masimo won $634 million verdict in separate California case.
• Final ITC decision still pending, could affect future sales.

Pulse Analysis

Apple’s health‑monitoring suite has become a differentiator in the premium smartwatch segment, with blood‑oxygen saturation (SpO2) readings touted as a vital sign for consumers. The original on‑watch sensor, introduced with the Series 9 and Ultra 2, ran afoul of Masimo’s patents covering optical detection methods, prompting an International Trade Commission (ITC) ban in late 2023. This regulatory hurdle highlighted the growing intersection of consumer electronics and medical‑device intellectual property, where even incremental feature upgrades can trigger costly litigation.

In response, Apple engineered a redesign that offloads the intensive signal‑processing algorithms to the paired iPhone, displaying results only on the phone’s screen. By altering the hardware‑software integration point, Apple effectively created a new claim architecture that sidesteps the specific patent claims upheld against the original design. This strategy reflects a broader industry trend: leveraging ecosystem flexibility to mitigate infringement risk while preserving user experience. It also raises questions about the future of on‑device health analytics as manufacturers balance regulatory compliance with the demand for real‑time, on‑wrist data.

The preliminary trade‑judge ruling restores Apple’s ability to sell the revised monitor, but the final ITC decision remains pending, leaving a cloud of uncertainty over long‑term market availability. Meanwhile, Masimo’s $634 million judgment in a separate federal case underscores the financial stakes of patent enforcement in the medical‑device arena. For investors and competitors, the outcome will influence supply‑chain planning, pricing power, and the pace of innovation in wearable health tech. Companies must now weigh the cost of redesigns against potential licensing agreements, as the legal landscape continues to shape the evolution of next‑generation health sensors.